drug affinity complex comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-21. Numbers and descriptions here follow the published literature rather than marketing material.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
. However, away from this reference point, errors will accumulate over time thus convergence test is needed to find an optimal time step for more accurate results. Among these three reproduction numbers,
=== Rejuva === Rejuva is an adeno-associated virus (AAV)-based gene therapy platform to enable the pancreas to produce GLP-1 on an ongoing basis as a treatment for obesity and type 2 diabetes. The therapy targets dysfunctional beta islet cells in the pancreas. Delivery is done with a needle catheter to deliver viral vectors into the pancreas. In January 2025, Rejuva completed Clinical Trial Application-enabling preclinical in vivo studies, beginning its first-in-human studies in the first half of 2025.
=== Electrochemical sensors === Electrochemical sensors can be used for label-free sensing of biomolecules. They detect changes and measure current between a probed metal electrode and an electrolyte containing the target analyte. A known potential to the electrode is then applied from a feedback current and the resulting current can be measured. For example, one technique using electrochemical sensing includes slowly raising the voltage causing chemical species at the electrode to be oxidized or reduced. Cell current vs voltage is plotted which can ultimately identify the quantity of chemical species consumed or produced at the electrode. Fluorescent tags can be used in conjunction with electrochemical sensors for ease of detection in a biological system.
A 4-month-old baby dies after a boat overloaded with more than 60 migrants sank attempting to cross the Channel from France to England. 2024 United Kingdom riots: Former childminder Lucy Connolly is sentenced to 31 months in prison over an online post in which she called for hotels housing asylum seekers to be set on fire. 18 October King Charles III and Queen Camilla arrive in Australia for their royal tour, Charles's first visit to the country since becoming King. The body of Scotland's former first minister, Alex Salmond, is flown back to Scotland from North Macedonia in a private jet paid for by Scottish businessman Tom Hunter. The Met Office warns of strong winds, potentially reaching 80 mph, along with heavy rain, ahead of the expected arrival of Storm Ashley. 647 migrants cross the English Channel. 19 October BBC News reports that the UK government is exploring how to hand over ownership of the Post Office to thousands of subpostmasters. In a Sunday Times interview, Olympic cyclist Sir Chris Hoy says that he has been told by doctors he has terminal cancer. 20 October The UK government announces plans to appoint a minister to oversee the building of HS2, as well as confirming it will not reinstate the route's Birmingham to Manchester leg. An amber weather alert is in place for western Scotland and the north and west of Northern Ireland as Storm Ashley arrives in the UK; yellow alerts are issued for other parts of Scotland, Northern Ireland and the Welsh coast.
== Politics == Christian Heritage Party (disambiguation) Christian Historical Party (1903–1908), a Dutch conservative party Republican People's Party (Cumhuriyet Halk Partisi), a Turkish centre-left party
Sources: en.wikipedia.org
However, Watson and Crick found fault in her steadfast assertion that, according to her data, a helical structure was not the only possible shape for DNA—so they had a dilemma. In an effort to clarify this issue, Max Ferdinand Perutz later published what had been in the progress report, and suggested that nothing was in the report that Franklin herself had not said in her talk (attended by Watson) in late 1951. Perutz explained that the report was to a Medical Research Council (MRC) committee that had been created to "establish contact between the different groups of people working for the Council". Randall's and Perutz's laboratories were both funded by the MRC. It is also not clear how important Franklin's unpublished results from the progress report actually were for the model-building done by Watson and Crick. After the first crude X-ray diffraction images of DNA were collected in the 1930s, William Astbury had talked about stacks of nucleotides spaced at 3.4 angström (0.34 nanometre) intervals in DNA. A citation to Astbury's earlier X-ray diffraction work was one of only eight references in Franklin's first paper on DNA. Analysis of Astbury's published DNA results and the better X-ray diffraction images collected by Wilkins and Franklin revealed the helical nature of DNA. It was possible to predict the number of bases stacked within a single turn of the DNA helix (10 per turn; a full turn of the helix is 27 angströms [2.7 nm] in the compact A form, 34 angströms [3.4 nm] in the wetter B form).
==== United States ==== ETH-LAD is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
=== Doug Rattmann === Doug Rattmann, often referred to as the "Ratman" is a character in both Portal and Portal 2. He was a former scientist working at Aperture and one of the few who survived when GLaDOS flooded the facility with neurotoxin. In the two games there are various "Ratman dens", where Doug Rattmann has left scribblings and paintings on walls in hidden rooms. Ratman's full appearance is only seen in the Portal 2: Lab Rat webcomic released by Valve prior to Portal 2's release to tie the story of the two games together. Ratman is the comic's main character. Prior to GLaDOS' rampancy and the neurotoxin release, Doug Rattmann was once an Aperture scientist. Already skeptical of the computer, the man fled from the gas and kept himself hidden from GLaDOS' view, slowly becoming more insane over an unknown stretch of time. Among the wall scribblings in the Portal dens is the sentence "The cake is a lie", which became an internet meme. The Lab Rat comic reveals that, despite his madness, Doug Rattmann identified Chell as a rejected test subject due to her high tenacity, and moved her to the top of the queue for testing. During events in Portal, he worked behind the scenes to scribble messages and warnings to Chell on the walls, leading her out of the testing chambers and towards GLaDOS. After watching her defeat the computer, he managed to escape the facility, but returned to assure Chell would be put in indefinite cryogenic storage animation after she was dragged back inside, suffering a serious injury (a shot in the leg from a turret) to complete this.
Feltenstein then took control of Thomas's care, even though he did not have admitting rights at St. Vincent's. The hospital's senior brain specialist, C. G. Gutierrez-Mahoney, was not called to examine Thomas until the afternoon of 6 November, some 36 hours after Thomas's admission. Caitlin, having flown from Britain, arrived at the hospital the following morning, by which time a tracheotomy had been performed. Her first words are reported to have been, "Is the bloody man dead yet?" Permitted to see Thomas for a short time, she returned, drunk, in the afternoon and made threats to John Brinnin. Feltenstein had her put into a straitjacket and committed to the River Crest Sanitarium. It is now believed that Thomas had been suffering from bronchitis, pneumonia, emphysema and asthma before his admission to St Vincent's. In their 2004 paper, Death by Neglect, D. N. Thomas and former GP Principal Simon Barton disclose that Thomas was found to have pneumonia when he was admitted to hospital in a coma. Doctors took three hours to restore his breathing, using artificial respiration and oxygen.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.